| 1411 |
National Cancer Institute |
Html |
en |
Lung Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing lung cancer and about research aimed at the prevention of this disease. |
| lung cancer screening | 0.598829 |
| beta-carotene cancer prevention | 0.582664 |
| Retinol Efficacy Trial | 0.5493 |
| World Cancer Research | 0.557661 |
| radiation-induced cancer risk | 0.558005 |
| Cancer Statistics Review | 0.554669 |
| Engl J Med | 0.601423 |
| lung cancer | 0.940569 |
| American Cancer Society | 0.565044 |
| new cancer cases | 0.561841 |
| cancer prevention study | 0.562495 |
| Lung cancer deaths | 0.600217 |
| Int J Cancer | 0.549565 |
| tobacco-specific lung carcinogen | 0.591137 |
| lung cancer survival | 0.624991 |
| lung cancers | 0.566409 |
| smoking-caused lung cancer | 0.618173 |
| Natl Cancer Inst | 0.828608 |
| increase lung cancer | 0.607425 |
| Clin Cancer Res | 0.548805 |
| lung cancer risks. | 0.611661 |
| et al. | 0.610801 |
| women | 0.552318 |
| lung cancer burden | 0.611188 |
| lung cancer risks | 0.615545 |
|
| Cancer Epidemiol Biomarkers | 0.562574 |
| Cancer Research Fund/American | 0.55766 |
| PUBMED Abstract | 0.579028 |
| cigarette smoking | 0.565154 |
| lung cancer rates | 0.635876 |
| National Cancer Institute | 0.583038 |
| high lung cancer | 0.622636 |
| primary lung cancer | 0.607733 |
| Abstract | 0.640461 |
| lung adenocarcinoma | 0.566862 |
| breast cancer | 0.562844 |
| 5-year lung cancer | 0.61828 |
| breast cancer radiotherapy | 0.549181 |
| lung cancer. | 0.565606 |
| physical activity | 0.552389 |
| Carotene Cancer Prevention | 0.55106 |
| lung cancer risk | 0.779552 |
| Low-dose lung | 0.559226 |
| increases lung cancer | 0.60774 |
| lung cancer risk. | 0.61153 |
| Public Health Service | 0.550531 |
| lung cancer mortality | 0.61452 |
| lung cancer incidence | 0.71571 |
| air pollution | 0.563747 |
|
CLICK HERE |
| 1431 |
National Cancer Institute |
Html |
en |
Prostate Cancer Prevention (PDQ®)–Patient Version |
Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease. |
| cancer risk factors | 0.382888 |
| cancer treatment | 0.345379 |
| cancer prevention trials | 0.393424 |
| prostate cancer prevention | 0.528023 |
| cancer protective factor | 0.370188 |
| prostate gland | 0.401353 |
| Prostate Cancer Events | 0.438643 |
| protective factors | 0.37428 |
| Cancer Information Service | 0.363767 |
| following PDQ summaries | 0.363098 |
| PDQ cancer information | 0.439164 |
| advanced prostate cancer | 0.435515 |
| high-grade prostate cancer | 0.447263 |
| Clinical Trials section | 0.34275 |
| prevention clinical trials | 0.365763 |
| male sex | 0.35549 |
| white men | 0.343088 |
| men | 0.418793 |
| Prevention Editorial Board | 0.367822 |
| treatment clinical trials | 0.342421 |
| National Cancer Institute | 0.410797 |
| clinical trials | 0.465084 |
| folic acid | 0.367544 |
|
| cancer information summary | 0.404534 |
| fewer prostate cancers | 0.434955 |
| Vitamin E Cancer | 0.36527 |
| new treatment | 0.346999 |
| localized prostate cancer | 0.435368 |
| breast cancer prevention | 0.361722 |
| Cancer Prevention Trial | 0.41435 |
| prostate cancer increases | 0.444676 |
| prostate cancer risk | 0.48237 |
| cancer patients | 0.343751 |
| Cancer Care page | 0.358977 |
| cancer risk factor | 0.385548 |
| NCI’s PDQ | 0.343309 |
| normal prostate growth | 0.414243 |
| PDQ summary | 0.356651 |
| aggressive prostate cancers | 0.429295 |
| NCI PDQ cancer | 0.383175 |
| prostate cancer | 0.982122 |
| bigger prostate | 0.40149 |
| cancer clinical trials | 0.368698 |
| risk factors | 0.422068 |
| cancer information summaries | 0.367063 |
| comprehensive cancer information | 0.367142 |
|
CLICK HERE |
| 1441 |
National Cancer Institute |
Html |
en |
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia. |
| Italy Leukemia Group | 0.492562 |
| bcr-abl tyrosine kinase | 0.570934 |
| adults | 0.459185 |
| earlier marrow regeneration | 0.455938 |
| allogeneic bone marrow | 0.517214 |
| acute lymphoid leukemias | 0.472448 |
| remission induction | 0.47757 |
| Gale RP | 0.454812 |
| imatinib mesylate | 0.472156 |
| chemotherapy | 0.474627 |
| Engl J Med | 0.498791 |
| bone marrow transplantation | 0.48642 |
| tyrosine kinase inhibitors | 0.483263 |
| Rapid marrow ablation | 0.456209 |
| acute myeloid leukemia | 0.613636 |
| leukemia group | 0.516396 |
| Adult Leukemia Study | 0.500665 |
| acute lymphocytic leukemia | 0.648415 |
| reverse-transcriptase polymerase chain | 0.482354 |
| Burkitt leukemia | 0.499236 |
| chronic myeloid leukemia | 0.493376 |
| remission rate | 0.456311 |
| remission induction regimen | 0.463491 |
| polymerase chain reaction | 0.48041 |
|
| bone marrow transplant | 0.489602 |
| white blood cell | 0.478936 |
| different fusion protein | 0.477591 |
| chromosomal abnormalities | 0.455367 |
| bone marrow biopsy | 0.472092 |
| Abstract | 0.51225 |
| patients | 0.592026 |
| hairy cell leukemia | 0.509021 |
| Clin Oncol | 0.480632 |
| chronic myelogenous leukemia | 0.543537 |
| bone marrow | 0.65205 |
| Philadelphia chromosome | 0.465482 |
| complete response rate | 0.474063 |
| remission induction treatment | 0.472074 |
| acute lymphoblastic leukemia | 0.938565 |
| complete remission | 0.520144 |
| bcr-abl fusion gene | 0.592307 |
| acute leukemia | 0.555648 |
| complete remission status | 0.464197 |
| High complete remission | 0.459577 |
| marrow remission | 0.460989 |
| bone marrow transplants | 0.462002 |
| neutropenic cancer patients | 0.462006 |
|
CLICK HERE |
| 1587 |
National Cancer Institute |
Html |
en |
Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version |
Treatment of children with rhabdomyosarcoma often includes chemotherapy, radiation therapy, and surgery. Learn about the signs, tests to diagnose, survival, treatment, and clinical trials for children with rhabdomyosarcoma in this expert-reviewed summary. |
| cancer treatment | 0.508808 |
| alveolar tumor | 0.397789 |
| tissue | 0.446976 |
| body | 0.557677 |
| type | 0.525643 |
| chemotherapy | 0.500597 |
| PDQ cancer information | 0.443489 |
| childhood rhabdomyosarcoma | 0.648755 |
| stereotaxic radiation therapy | 0.400999 |
| embryonal tumor | 0.43303 |
| clinical trials | 0.703451 |
| rhabdomyosarcoma | 0.676649 |
| nearby lymph nodes | 0.746635 |
| cancer information summary | 0.418411 |
| rhabdomyosarcoma cells | 0.404898 |
| clinical trial | 0.53997 |
| sentinel lymph node | 0.434722 |
| malignant tumor cells | 0.470546 |
| body radiation therapy | 0.454423 |
| lymph nodes | 0.791456 |
| radiation therapy machine | 0.400658 |
| radiation therapy | 0.98278 |
| beam radiation therapy | 0.399186 |
| soft tissue sarcoma | 0.440069 |
|
| treatment | 0.729346 |
| wide local excision | 0.482565 |
| cancer cells | 0.726714 |
| Conformal radiation therapy | 0.416835 |
| treatment clinical trials | 0.409517 |
| stereotactic body radiation | 0.441552 |
| National Cancer Institute | 0.429355 |
| spinal cord | 0.406531 |
| metastatic rhabdomyosarcoma | 0.428908 |
| effects cancer treatment | 0.408271 |
| new treatment | 0.425898 |
| Intensity-modulated radiation therapy | 0.401599 |
| external-beam radiation therapy | 0.401022 |
| external radiation therapy | 0.507659 |
| primary tumor | 0.410338 |
| metastatic tumor | 0.420784 |
| Childhood Rhabdomyosarcoma Treatment | 0.412835 |
| bone marrow | 0.399523 |
| cancer clinical trials | 0.406325 |
| interstitial radiation therapy | 0.400167 |
| tumor | 0.799626 |
| recurrent rhabdomyosarcoma | 0.413207 |
| internal radiation therapy | 0.435661 |
| cancer | 0.935623 |
|
CLICK HERE |
| 1608 |
National Cancer Institute |
Html |
en |
Stomach (Gastric) Cancer Screening (PDQ®)–Patient Version |
There is no standard or routine screening test for stomach (gastric) cancer. Stomach (gastric) cancer is not common in the U.S. Learn about tests that have been studied to detect or screen for stomach cancer in this expert-reviewed summary. |
| PDQ Screening | 0.53696 |
| Serum pepsinogen levels | 0.476069 |
| cancer treatment | 0.489595 |
| better food storage | 0.483291 |
| cancer screening methods | 0.571194 |
| United States | 0.52237 |
| ongoing clinical trials | 0.488517 |
| screening tests | 0.527906 |
| silver-white metallic compound | 0.475608 |
| following PDQ summaries | 0.550231 |
| Cancer Information Service | 0.528818 |
| PDQ cancer information | 0.69988 |
| Prevention Editorial Board | 0.538784 |
| treatment clinical trials | 0.487954 |
| National Cancer Institute | 0.62168 |
| clinical trials | 0.622347 |
| PDQ documents | 0.494877 |
| test result | 0.484679 |
| cancer information summary | 0.615581 |
| cancer doctors | 0.478532 |
| clinical trial | 0.495039 |
| new treatment | 0.490527 |
| breast cancer prevention | 0.511108 |
|
| test results | 0.482671 |
| risk factors | 0.481306 |
| Cancer screening trials | 0.577316 |
| false-positive test result | 0.478411 |
| cancer patients | 0.482925 |
| Cancer Care page | 0.515504 |
| PDQ database | 0.499197 |
| latest published information | 0.490927 |
| PDQ® Screening | 0.477124 |
| NCI’s PDQ | 0.504099 |
| risk factor | 0.478731 |
| PDQ summary | 0.519732 |
| cancer symptoms | 0.504928 |
| NCI PDQ cancer | 0.579122 |
| certain risk factors | 0.477251 |
| lower salt intake | 0.475762 |
| tests | 0.5444 |
| stomach cancer | 0.956427 |
| cancer information summaries | 0.536975 |
| comprehensive cancer information | 0.53624 |
| Upper endoscopy | 0.478371 |
| stomach cancer screening | 0.661237 |
|
CLICK HERE |
| 1635 |
National Cancer Institute |
Html |
en |
Cancell/Cantron/Protocel (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of Cancell/Entelev as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| treatment | 0.59635 |
| peer-reviewed scientific journals | 0.520434 |
| cancer treatment | 0.437142 |
| cancer prevention | 0.377301 |
| Complementary Therapies Editorial | 0.493039 |
| United States | 0.466761 |
| Drug Administration | 0.651254 |
| Cancer Information Specialist | 0.403618 |
| cancer cells | 0.478684 |
| Cancer Information Service | 0.547985 |
| liquid mixture Cancell | 0.377167 |
| PDQ cancer information | 0.676104 |
| Cancer Complementary | 0.434191 |
| CAM therapies | 0.389658 |
| Cancell | 0.664087 |
| treatment clinical trials | 0.370761 |
| National Cancer Institute | 0.97945 |
| studies | 0.373926 |
| clinical trials | 0.769435 |
| alternative medicine | 0.540927 |
| U.S. Food | 0.518657 |
| conventional treatment | 0.383649 |
| health care | 0.363873 |
| cancer information summary | 0.557509 |
|
| scientific journals | 0.541722 |
| alternative cancer therapies | 0.42141 |
| Federal Trade Commission | 0.393843 |
| National Institutes | 0.378494 |
| clinical trial | 0.410446 |
| National Center | 0.359319 |
| CAM cancer research | 0.395503 |
| new treatment | 0.357379 |
| breast cancer prevention | 0.372403 |
| PDQ health | 0.366183 |
| cancer patients | 0.43176 |
| Cancer Care page | 0.374735 |
| health | 0.389384 |
| NCI’s PDQ | 0.383229 |
| PDQ summary | 0.396491 |
| Integrative Health | 0.358164 |
| NCI PDQ cancer | 0.499567 |
| cancer information database | 0.420231 |
| alternative therapies | 0.478182 |
| cancer information summaries | 0.420966 |
| Therapies Editorial Board | 0.444837 |
| research studies | 0.372726 |
| conventional treatments | 0.361723 |
|
CLICK HERE |
| 1636 |
National Cancer Institute |
Html |
en |
Cartilage (Bovine and Shark) (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| cancer treatment | 0.483107 |
| human cancer cells | 0.399726 |
| cartilage treatment | 0.54785 |
| shark cartilage | 0.911115 |
| PDQ cancer information | 0.489648 |
| Cancer Complementary | 0.397259 |
| lung cancer | 0.396037 |
| new blood vessels | 0.529873 |
| blood vessel growth | 0.688109 |
| clinical trials | 0.661965 |
| testing bovine cartilage | 0.553086 |
| powdered cartilage products | 0.528871 |
| bovine cartilage | 0.754583 |
| cancer information summary | 0.450971 |
| clinical trial | 0.545778 |
| patients | 0.414137 |
| randomized clinical trial | 0.405563 |
| NCI PDQ cancer | 0.409125 |
| cancer information database | 0.395004 |
| liquid shark cartilage | 0.530016 |
| liquid cartilage products | 0.569642 |
| powdered shark cartilage | 0.613657 |
| cancer information | 0.501779 |
| breast cancer cells | 0.394321 |
|
| shark cartilage products | 0.633195 |
| laboratory study | 0.408409 |
| cartilage products | 0.782377 |
| Complementary Therapies Editorial | 0.405419 |
| cancer cells | 0.530307 |
| Cancer Information Service | 0.450397 |
| preclinical studies | 0.47111 |
| cartilage product AE–941/Neovastat | 0.510074 |
| dietary supplements | 0.394341 |
| National Cancer Institute | 0.540172 |
| studies | 0.47228 |
| alternative medicine | 0.440784 |
| pancreatic cancer cells | 0.3965 |
| human cartilage | 0.495387 |
| PDQ Cartilage | 0.50056 |
| shark cartilage product | 0.665863 |
| cartilage | 0.96677 |
| animal studies | 0.448189 |
| standard cancer treatment | 0.405448 |
| alternative therapies | 0.399716 |
| cancer information summaries | 0.395389 |
| powdered cartilage | 0.59313 |
| bovine cartilage product | 0.523261 |
| cancer | 0.811115 |
|
CLICK HERE |
| 1975 |
National Cancer Institute |
Html |
es |
Etapa final de la vida (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre lo que debe ser el cuidado desde los últimos días hasta las últimas horas de vida, esto incluye los síntomas comunes, dilemas éticos que podrían surgir, y la función que desempeña el oncólogo en proveer cuidados al paciente y su familia durante este tiempo. |
| palliative care experts | 0.23431 |
| with medical care | 0.241191 |
| discuss palliative care | 0.233699 |
| Symptom Assessment | 0.232929 |
| puntaje pps | 0.250501 |
| Chisholm G | 0.239654 |
| impending death | 0.225195 |
| American Cancer Society | 0.325883 |
| mioclonÃa inducida | 0.230408 |
| signos tardÃos | 0.255455 |
| cancer care | 0.288204 |
| Cancer Patients Admitted | 0.244551 |
| Early palliative care | 0.234581 |
| Palliative Care Units | 0.231229 |
| cancer patients | 0.700067 |
| intensidad promedio | 0.222271 |
| Palliative Performance Scale | 0.307144 |
| PDQ Delirium | 0.245083 |
| respiración cheyne-stokes | 0.226557 |
| Symptom Assessment Scale | 0.224548 |
| End-of-Life Cancer Care | 0.259456 |
| hospitalized patients with | 0.234983 |
| patients with | 0.788026 |
| determinados pacientes | 0.252968 |
| Pain Symptom Manage | 0.940988 |
|
| care cancer | 0.276344 |
| delirium hiperactivo | 0.272295 |
| Santos R | 0.261547 |
| cohort study | 0.227764 |
| patients with metastatic | 0.238354 |
| Cancer Facts | 0.237968 |
| palliative care | 0.397902 |
| Morita T | 0.262872 |
| end-of-life discussion | 0.224231 |
| Hosp Palliat Care | 0.228606 |
| critical care setting | 0.224616 |
| treating delirium | 0.237587 |
| ill adult patients | 0.223449 |
| correlations with quality | 0.226302 |
| clinical signs | 0.22445 |
| canadian tertiary care | 0.2263 |
| Intern Med | 0.224374 |
| Clin Oncol | 0.327109 |
| Bruera E | 0.232399 |
| terminal care | 0.223061 |
| systematic review | 0.239239 |
| medical care | 0.24121 |
| spiritual care | 0.22381 |
| Care Med | 0.223485 |
|
CLICK HERE |
| 3963 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de orofaringe (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de orofaringe. |
| tratamiento.Ciertas formas | 0.441948 |
| Neck Cancer | 0.50872 |
| siguientes procedimientos | 0.637903 |
| corporal estereotáctica | 0.73941 |
| estadio iv | 0.619806 |
| hormona tiroidea | 0.524054 |
| siguientes elementos | 0.501559 |
| estadio ii | 0.502031 |
| rayos x | 0.464154 |
| pequeñas marcas | 0.437304 |
| estadio ivc | 0.501067 |
| enlace drugs approved | 0.605888 |
| orofaringe ayuda | 0.523898 |
| aguja fina.Se | 0.467807 |
| PDQ Consumo | 0.531679 |
|
| estadio iva | 0.502486 |
| vÃas respiratorias | 0.466653 |
| cirujano manipula herramientas | 0.481463 |
| pequeñas mejora | 0.437701 |
| National Cancer Institute | 0.433607 |
| siguientes riesgos | 0.427789 |
| Instituto Nacional | 0.463265 |
| malla ayuda | 0.439384 |
| PDQ Tratamiento | 0.485984 |
| Physician Data Query | 0.531575 |
| radioterapia hiperfraccionada | 0.624557 |
| ganglio linfático mide | 0.948968 |
| cáncer.ampliar radioterapia | 0.563245 |
| distinta intensidad | 0.445146 |
| siguientes sumarios | 0.538888 |
|
CLICK HERE |
| 4394 |
National Cancer Institute |
Html |
null |
Blue Ribbon Panel Working Groups |
Seven working groups comprised of leading experts from the cancer community have been charged with developing recommendations for the Cancer Moonshot Initiative. |
|
|
CLICK HERE |